Shopping Cart 0
Cart Subtotal
AED 0

Pharmaceuticals in Scandinavia

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 1285

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 2569

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 3854
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Pharmaceuticals in Scandinavia

Summary

Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The Scandinavian pharmaceuticals market had total revenues of USD 13.1m in 2018, representing a compound annual rate of change (CARC) of -2.6% between 2014 and 2018.

- The performance of the market is forecast to decline further but at a slower pace, with an anticipated CARC of -0.2% for the five-year period 2018-2023, which is expected to drive the market to a value of USD 13.0m by the end of 2023.

- Scandinavian pharmaceuticals market is driven by nationalized healthcare systems and a strong research-base.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Scandinavia

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia

- Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the Scandinavia pharmaceuticals market by value in 2018?

- What will be the size of the Scandinavia pharmaceuticals market in 2023?

- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?

- How has the market performed over the last five years?

- How large is Scandinavia's pharmaceuticals market in relation to its regional counterparts?

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Market value

Market value forecast

Geography segmentation

Market share

Market rivalry

Market Overview

Market definition

Market analysis

Market Data

Market value

Market Segmentation

Geography segmentation

Market share

Market Outlook

Market value forecast

Five Forces Analysis

Summary

Buyer power

Supplier power

New entrants

Threat of substitutes

Degree of rivalry

Leading Companies

Novartis AG

Pfizer Inc

F. Hoffmann-La Roche Ltd

Sanofi SA

Methodology

Industry associations

Related MarketLine research

Appendix

About MarketLine


List Of Figure

List of Figures

Figure 1: Scandinavia pharmaceuticals market value: USD billion, 2014-18

Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2018

Figure 3: Scandinavia pharmaceuticals market share: % share, by value, 2018

Figure 4: Scandinavia pharmaceuticals market value forecast: USD billion, 2018-23

Figure 5: Forces driving competition in the pharmaceuticals market in Scandinavia, 2018

Figure 6: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2018

Figure 7: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2018

Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2018

Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2018

Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2018

Figure 11: Novartis AG: revenues & profitability

Figure 12: Novartis AG: assets & liabilities

Figure 13: Pfizer Inc: revenues & profitability

Figure 14: Pfizer Inc: assets & liabilities

Figure 15: F. Hoffmann-La Roche Ltd: revenues & profitability

Figure 16: F. Hoffmann-La Roche Ltd: assets & liabilities

Figure 17: Sanofi SA: revenues & profitability

Figure 18: Sanofi SA: assets & liabilities


List Of Table

List of Tables

Table 1: Scandinavia pharmaceuticals market value: USD billion, 2014-18

Table 2: Scandinavia pharmaceuticals market geography segmentation: USD billion, 2018

Table 3: Scandinavia pharmaceuticals market share: % share, by value, 2018

Table 4: Scandinavia pharmaceuticals market value forecast: USD billion, 2018-23

Table 5: Novartis AG: key facts

Table 6: Novartis AG: key financials (USD )

Table 7: Novartis AG: key financial ratios

Table 8: Pfizer Inc: key facts

Table 9: Pfizer Inc: key financials (USD )

Table 10: Pfizer Inc: key financial ratios

Table 11: F. Hoffmann-La Roche Ltd: key facts

Table 12: F. Hoffmann-La Roche Ltd: key financials (USD )

Table 13: F. Hoffmann-La Roche Ltd: key financials (CHF)

Table 14: F. Hoffmann-La Roche Ltd: key financial ratios

Table 15: Sanofi SA: key facts

Table 16: Sanofi SA: key financials (USD )

Table 17: Sanofi SA: key financials (EUR)

Table 18: Sanofi SA: key financial ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Novartis AG

Pfizer Inc

F. Hoffmann-La Roche Ltd

Sanofi SA

Pharmaceuticals in Scandinavia

Summary

Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The Scandinavian pharmaceuticals market had total revenues of USD 13.1m in 2018, representing a compound annual rate of change (CARC) of -2.6% between 2014 and 2018.

- The performance of the market is forecast to decline further but at a slower pace, with an anticipated CARC of -0.2% for the five-year period 2018-2023, which is expected to drive the market to a value of USD 13.0m by the end of 2023.

- Scandinavian pharmaceuticals market is driven by nationalized healthcare systems and a strong research-base.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Scandinavia

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia

- Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the Scandinavia pharmaceuticals market by value in 2018?

- What will be the size of the Scandinavia pharmaceuticals market in 2023?

- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?

- How has the market performed over the last five years?

- How large is Scandinavia's pharmaceuticals market in relation to its regional counterparts?

READ MORE

Scope

Table of Contents

Executive Summary

Market value

Market value forecast

Geography segmentation

Market share

Market rivalry

Market Overview

Market definition

Market analysis

Market Data

Market value

Market Segmentation

Geography segmentation

Market share

Market Outlook

Market value forecast

Five Forces Analysis

Summary

Buyer power

Supplier power

New entrants

Threat of substitutes

Degree of rivalry

Leading Companies

Novartis AG

Pfizer Inc

F. Hoffmann-La Roche Ltd

Sanofi SA

Methodology

Industry associations

Related MarketLine research

Appendix

About MarketLine


List Of Figure

List of Figures

Figure 1: Scandinavia pharmaceuticals market value: USD billion, 2014-18

Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2018

Figure 3: Scandinavia pharmaceuticals market share: % share, by value, 2018

Figure 4: Scandinavia pharmaceuticals market value forecast: USD billion, 2018-23

Figure 5: Forces driving competition in the pharmaceuticals market in Scandinavia, 2018

Figure 6: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2018

Figure 7: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2018

Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2018

Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2018

Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2018

Figure 11: Novartis AG: revenues & profitability

Figure 12: Novartis AG: assets & liabilities

Figure 13: Pfizer Inc: revenues & profitability

Figure 14: Pfizer Inc: assets & liabilities

Figure 15: F. Hoffmann-La Roche Ltd: revenues & profitability

Figure 16: F. Hoffmann-La Roche Ltd: assets & liabilities

Figure 17: Sanofi SA: revenues & profitability

Figure 18: Sanofi SA: assets & liabilities


List Of Table

List of Tables

Table 1: Scandinavia pharmaceuticals market value: USD billion, 2014-18

Table 2: Scandinavia pharmaceuticals market geography segmentation: USD billion, 2018

Table 3: Scandinavia pharmaceuticals market share: % share, by value, 2018

Table 4: Scandinavia pharmaceuticals market value forecast: USD billion, 2018-23

Table 5: Novartis AG: key facts

Table 6: Novartis AG: key financials (USD )

Table 7: Novartis AG: key financial ratios

Table 8: Pfizer Inc: key facts

Table 9: Pfizer Inc: key financials (USD )

Table 10: Pfizer Inc: key financial ratios

Table 11: F. Hoffmann-La Roche Ltd: key facts

Table 12: F. Hoffmann-La Roche Ltd: key financials (USD )

Table 13: F. Hoffmann-La Roche Ltd: key financials (CHF)

Table 14: F. Hoffmann-La Roche Ltd: key financial ratios

Table 15: Sanofi SA: key facts

Table 16: Sanofi SA: key financials (USD )

Table 17: Sanofi SA: key financials (EUR)

Table 18: Sanofi SA: key financial ratios

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Novartis AG

Pfizer Inc

F. Hoffmann-La Roche Ltd

Sanofi SA